High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains

•AS LNA qPCR can accurately identify VP1-E295K containing samples in sPV2 batches.•The developed AS LNA qPCR for E295K mutation is highly sensitive.•LNA probes used are highly specific in targeting known mutations.•AS LNA qPCR is likely applicable to other vaccine strains, serotypes, and mutations....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2024-04, Vol.42 (9), p.2475-2484
Hauptverfasser: Opmeer, Lizet, Gazzoli, Isabella, Ballmann, Mónika, Willemsen, Marieke, Voshol, Gerben P., Grudniewska-Lawton, Magda, Havenga, Menzo, Yallop, Christopher, Hamidi, Ahd, Gillissen, Gert, Bakker, Wilfried A.M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2484
container_issue 9
container_start_page 2475
container_title Vaccine
container_volume 42
creator Opmeer, Lizet
Gazzoli, Isabella
Ballmann, Mónika
Willemsen, Marieke
Voshol, Gerben P.
Grudniewska-Lawton, Magda
Havenga, Menzo
Yallop, Christopher
Hamidi, Ahd
Gillissen, Gert
Bakker, Wilfried A.M.
description •AS LNA qPCR can accurately identify VP1-E295K containing samples in sPV2 batches.•The developed AS LNA qPCR for E295K mutation is highly sensitive.•LNA probes used are highly specific in targeting known mutations.•AS LNA qPCR is likely applicable to other vaccine strains, serotypes, and mutations. Sabin Inactivated Poliovirus Vaccine (sIPV) has become one of the preferred vaccination options for the last step in the Poliovirus eradication program. Sequencing of poliovirus samples is needed during the manufacturing of poliovirus vaccines to assure the safety and immunogenicity of these vaccines. Next-generation sequencing analysis is the current costly and time-consuming gold standard for monitoring the manufacturing processes. We developed a low-cost and quick, highly sensitive, and allele-specific locked nucleic acid-probe-based reverse transcription quantitative PCR alternative that can accurately detect mutations in poliovirus vaccine samples during process development, scaling up, and release. Using the frequently in vitro occurring and viral replication-impacting VP1-E295K mutation as a showcase, we show that this technology can accurately detect E295K mutations in poliovirus 2 samples to similar levels as NGS. The qPCR technology was developed employing a synthetic dsDNA fragment-based standard curve containing mixes of E295K-WT (wildtype) and Mut (mutant) synthetic dsDNA fragments ranging from 1 × 107 copies/µL to 1 × 102 copies/µL to achieve a linear correlation with R2 > 0.999, and PCR efficiencies of 95–105 %. Individual standard concentration levels achieved accuracies of ≥92 % (average 96 %) and precisions of ≤17 % (average 3.3 %) RSD. Specificity of locked nucleic acid (LNA)-probes was confirmed in the presence and absence of co-mutations in the probe-binding region. Application of the developed assay to Sabin Poliovirus type 2 production run samples, illustrated a linear relationship with an R2 of 0.994, and an average accuracy of 97.2 % of the variant (allele)-specific AS LNA qPCR result, compared to NGS. The assay showed good sensitivity for poliovirus samples, containing E295K mutation levels between 0 % and 95 % (quantification range). In conclusion, the developed AS LNA qPCR presents a valuable low-cost, and fast tool, suitable for the process development and quality control of polio vaccines.
doi_str_mv 10.1016/j.vaccine.2024.01.103
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11007389</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X24001300</els_id><sourcerecordid>3153183633</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-664fb8cab629be8d9aee793df346d526fb79c37cea417d48fab38790ee0950af3</originalsourceid><addsrcrecordid>eNqFUV2L1DAUDaK44-pPUAK--NLxpmmT9kmGYXWFQcUP8C2k6c00Q9t0k3bAf2_GHdePl4VA4NyTc0_OIeQ5gzUDJl4f1kdtjBtxnUNerIElmD8gK1ZJnuUlqx6SFeSiyAoG3y_IkxgPAFByVj8mF7wqgQsBK-Ku3b6jcxf8su-mZaabL3T3YUNvPm0_0wHnzrfU-pAYSFuc0czOj9Rbqmmc0DjrDB2WWf-C3Ugn3zt_dGGJ9OyPxjloN8an5JHVfcRn5_uSfHt79XV7ne0-vnu_3ewyU0g5Z0IUtqmMbkReN1i1tUaUNW8tL0Rb5sI2sjZcGtQFk21RWd3wStaACHUJ2vJL8uZWd1qaAVuDY9rfqym4QYcfymun_p2MrlN7f1SMAUhe1Unh1Vkh-JsF46wGFw32vR7RL1FxlmKsuOD8Xmpey1xCOkWivvyPevBLGFMUigNnogLgeWKVtywTfIwB7Z1xBupUvDqoc7DqVLwCluCTkRd___ru1e-m_8SCKfujw6CicTgabF1IrarWu3tW_AS5zMKE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3031680032</pqid></control><display><type>article</type><title>High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains</title><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Opmeer, Lizet ; Gazzoli, Isabella ; Ballmann, Mónika ; Willemsen, Marieke ; Voshol, Gerben P. ; Grudniewska-Lawton, Magda ; Havenga, Menzo ; Yallop, Christopher ; Hamidi, Ahd ; Gillissen, Gert ; Bakker, Wilfried A.M.</creator><creatorcontrib>Opmeer, Lizet ; Gazzoli, Isabella ; Ballmann, Mónika ; Willemsen, Marieke ; Voshol, Gerben P. ; Grudniewska-Lawton, Magda ; Havenga, Menzo ; Yallop, Christopher ; Hamidi, Ahd ; Gillissen, Gert ; Bakker, Wilfried A.M.</creatorcontrib><description>•AS LNA qPCR can accurately identify VP1-E295K containing samples in sPV2 batches.•The developed AS LNA qPCR for E295K mutation is highly sensitive.•LNA probes used are highly specific in targeting known mutations.•AS LNA qPCR is likely applicable to other vaccine strains, serotypes, and mutations. Sabin Inactivated Poliovirus Vaccine (sIPV) has become one of the preferred vaccination options for the last step in the Poliovirus eradication program. Sequencing of poliovirus samples is needed during the manufacturing of poliovirus vaccines to assure the safety and immunogenicity of these vaccines. Next-generation sequencing analysis is the current costly and time-consuming gold standard for monitoring the manufacturing processes. We developed a low-cost and quick, highly sensitive, and allele-specific locked nucleic acid-probe-based reverse transcription quantitative PCR alternative that can accurately detect mutations in poliovirus vaccine samples during process development, scaling up, and release. Using the frequently in vitro occurring and viral replication-impacting VP1-E295K mutation as a showcase, we show that this technology can accurately detect E295K mutations in poliovirus 2 samples to similar levels as NGS. The qPCR technology was developed employing a synthetic dsDNA fragment-based standard curve containing mixes of E295K-WT (wildtype) and Mut (mutant) synthetic dsDNA fragments ranging from 1 × 107 copies/µL to 1 × 102 copies/µL to achieve a linear correlation with R2 &gt; 0.999, and PCR efficiencies of 95–105 %. Individual standard concentration levels achieved accuracies of ≥92 % (average 96 %) and precisions of ≤17 % (average 3.3 %) RSD. Specificity of locked nucleic acid (LNA)-probes was confirmed in the presence and absence of co-mutations in the probe-binding region. Application of the developed assay to Sabin Poliovirus type 2 production run samples, illustrated a linear relationship with an R2 of 0.994, and an average accuracy of 97.2 % of the variant (allele)-specific AS LNA qPCR result, compared to NGS. The assay showed good sensitivity for poliovirus samples, containing E295K mutation levels between 0 % and 95 % (quantification range). In conclusion, the developed AS LNA qPCR presents a valuable low-cost, and fast tool, suitable for the process development and quality control of polio vaccines.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2024.01.103</identifier><identifier>PMID: 38503660</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Acids ; Alleles ; AS LNA qPCR ; Cost analysis ; DNA ; Enterovirus C ; Immunogenicity ; Invoices ; Low cost ; Manufacturing ; Manufacturing industry ; mutants ; Mutation ; Mutations ; Next-generation sequencing ; NGS ; Nucleic acids ; Poliomyelitis ; Poliovirus ; Polymerase chain reaction ; qPCR ; Quality control ; reverse transcriptase polymerase chain reaction ; Reverse transcription ; Sabin Poliovirus 2 ; Sarcoma ; Sequence analysis ; sIPV ; vaccination ; Vaccine ; Vaccines ; VP1 protein ; VP1-E295K</subject><ispartof>Vaccine, 2024-04, Vol.42 (9), p.2475-2484</ispartof><rights>2024 The Author(s)</rights><rights>Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.</rights><rights>2024. The Author(s)</rights><rights>2024 The Author(s) 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c477t-664fb8cab629be8d9aee793df346d526fb79c37cea417d48fab38790ee0950af3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/3031680032?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,778,782,883,3539,27907,27908,45978,64366,64368,64370,72220</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38503660$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Opmeer, Lizet</creatorcontrib><creatorcontrib>Gazzoli, Isabella</creatorcontrib><creatorcontrib>Ballmann, Mónika</creatorcontrib><creatorcontrib>Willemsen, Marieke</creatorcontrib><creatorcontrib>Voshol, Gerben P.</creatorcontrib><creatorcontrib>Grudniewska-Lawton, Magda</creatorcontrib><creatorcontrib>Havenga, Menzo</creatorcontrib><creatorcontrib>Yallop, Christopher</creatorcontrib><creatorcontrib>Hamidi, Ahd</creatorcontrib><creatorcontrib>Gillissen, Gert</creatorcontrib><creatorcontrib>Bakker, Wilfried A.M.</creatorcontrib><title>High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>•AS LNA qPCR can accurately identify VP1-E295K containing samples in sPV2 batches.•The developed AS LNA qPCR for E295K mutation is highly sensitive.•LNA probes used are highly specific in targeting known mutations.•AS LNA qPCR is likely applicable to other vaccine strains, serotypes, and mutations. Sabin Inactivated Poliovirus Vaccine (sIPV) has become one of the preferred vaccination options for the last step in the Poliovirus eradication program. Sequencing of poliovirus samples is needed during the manufacturing of poliovirus vaccines to assure the safety and immunogenicity of these vaccines. Next-generation sequencing analysis is the current costly and time-consuming gold standard for monitoring the manufacturing processes. We developed a low-cost and quick, highly sensitive, and allele-specific locked nucleic acid-probe-based reverse transcription quantitative PCR alternative that can accurately detect mutations in poliovirus vaccine samples during process development, scaling up, and release. Using the frequently in vitro occurring and viral replication-impacting VP1-E295K mutation as a showcase, we show that this technology can accurately detect E295K mutations in poliovirus 2 samples to similar levels as NGS. The qPCR technology was developed employing a synthetic dsDNA fragment-based standard curve containing mixes of E295K-WT (wildtype) and Mut (mutant) synthetic dsDNA fragments ranging from 1 × 107 copies/µL to 1 × 102 copies/µL to achieve a linear correlation with R2 &gt; 0.999, and PCR efficiencies of 95–105 %. Individual standard concentration levels achieved accuracies of ≥92 % (average 96 %) and precisions of ≤17 % (average 3.3 %) RSD. Specificity of locked nucleic acid (LNA)-probes was confirmed in the presence and absence of co-mutations in the probe-binding region. Application of the developed assay to Sabin Poliovirus type 2 production run samples, illustrated a linear relationship with an R2 of 0.994, and an average accuracy of 97.2 % of the variant (allele)-specific AS LNA qPCR result, compared to NGS. The assay showed good sensitivity for poliovirus samples, containing E295K mutation levels between 0 % and 95 % (quantification range). In conclusion, the developed AS LNA qPCR presents a valuable low-cost, and fast tool, suitable for the process development and quality control of polio vaccines.</description><subject>Acids</subject><subject>Alleles</subject><subject>AS LNA qPCR</subject><subject>Cost analysis</subject><subject>DNA</subject><subject>Enterovirus C</subject><subject>Immunogenicity</subject><subject>Invoices</subject><subject>Low cost</subject><subject>Manufacturing</subject><subject>Manufacturing industry</subject><subject>mutants</subject><subject>Mutation</subject><subject>Mutations</subject><subject>Next-generation sequencing</subject><subject>NGS</subject><subject>Nucleic acids</subject><subject>Poliomyelitis</subject><subject>Poliovirus</subject><subject>Polymerase chain reaction</subject><subject>qPCR</subject><subject>Quality control</subject><subject>reverse transcriptase polymerase chain reaction</subject><subject>Reverse transcription</subject><subject>Sabin Poliovirus 2</subject><subject>Sarcoma</subject><subject>Sequence analysis</subject><subject>sIPV</subject><subject>vaccination</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>VP1 protein</subject><subject>VP1-E295K</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFUV2L1DAUDaK44-pPUAK--NLxpmmT9kmGYXWFQcUP8C2k6c00Q9t0k3bAf2_GHdePl4VA4NyTc0_OIeQ5gzUDJl4f1kdtjBtxnUNerIElmD8gK1ZJnuUlqx6SFeSiyAoG3y_IkxgPAFByVj8mF7wqgQsBK-Ku3b6jcxf8su-mZaabL3T3YUNvPm0_0wHnzrfU-pAYSFuc0czOj9Rbqmmc0DjrDB2WWf-C3Ugn3zt_dGGJ9OyPxjloN8an5JHVfcRn5_uSfHt79XV7ne0-vnu_3ewyU0g5Z0IUtqmMbkReN1i1tUaUNW8tL0Rb5sI2sjZcGtQFk21RWd3wStaACHUJ2vJL8uZWd1qaAVuDY9rfqym4QYcfymun_p2MrlN7f1SMAUhe1Unh1Vkh-JsF46wGFw32vR7RL1FxlmKsuOD8Xmpey1xCOkWivvyPevBLGFMUigNnogLgeWKVtywTfIwB7Z1xBupUvDqoc7DqVLwCluCTkRd___ru1e-m_8SCKfujw6CicTgabF1IrarWu3tW_AS5zMKE</recordid><startdate>20240402</startdate><enddate>20240402</enddate><creator>Opmeer, Lizet</creator><creator>Gazzoli, Isabella</creator><creator>Ballmann, Mónika</creator><creator>Willemsen, Marieke</creator><creator>Voshol, Gerben P.</creator><creator>Grudniewska-Lawton, Magda</creator><creator>Havenga, Menzo</creator><creator>Yallop, Christopher</creator><creator>Hamidi, Ahd</creator><creator>Gillissen, Gert</creator><creator>Bakker, Wilfried A.M.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><general>Elsevier Science</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope></search><sort><creationdate>20240402</creationdate><title>High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains</title><author>Opmeer, Lizet ; Gazzoli, Isabella ; Ballmann, Mónika ; Willemsen, Marieke ; Voshol, Gerben P. ; Grudniewska-Lawton, Magda ; Havenga, Menzo ; Yallop, Christopher ; Hamidi, Ahd ; Gillissen, Gert ; Bakker, Wilfried A.M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-664fb8cab629be8d9aee793df346d526fb79c37cea417d48fab38790ee0950af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acids</topic><topic>Alleles</topic><topic>AS LNA qPCR</topic><topic>Cost analysis</topic><topic>DNA</topic><topic>Enterovirus C</topic><topic>Immunogenicity</topic><topic>Invoices</topic><topic>Low cost</topic><topic>Manufacturing</topic><topic>Manufacturing industry</topic><topic>mutants</topic><topic>Mutation</topic><topic>Mutations</topic><topic>Next-generation sequencing</topic><topic>NGS</topic><topic>Nucleic acids</topic><topic>Poliomyelitis</topic><topic>Poliovirus</topic><topic>Polymerase chain reaction</topic><topic>qPCR</topic><topic>Quality control</topic><topic>reverse transcriptase polymerase chain reaction</topic><topic>Reverse transcription</topic><topic>Sabin Poliovirus 2</topic><topic>Sarcoma</topic><topic>Sequence analysis</topic><topic>sIPV</topic><topic>vaccination</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>VP1 protein</topic><topic>VP1-E295K</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Opmeer, Lizet</creatorcontrib><creatorcontrib>Gazzoli, Isabella</creatorcontrib><creatorcontrib>Ballmann, Mónika</creatorcontrib><creatorcontrib>Willemsen, Marieke</creatorcontrib><creatorcontrib>Voshol, Gerben P.</creatorcontrib><creatorcontrib>Grudniewska-Lawton, Magda</creatorcontrib><creatorcontrib>Havenga, Menzo</creatorcontrib><creatorcontrib>Yallop, Christopher</creatorcontrib><creatorcontrib>Hamidi, Ahd</creatorcontrib><creatorcontrib>Gillissen, Gert</creatorcontrib><creatorcontrib>Bakker, Wilfried A.M.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Opmeer, Lizet</au><au>Gazzoli, Isabella</au><au>Ballmann, Mónika</au><au>Willemsen, Marieke</au><au>Voshol, Gerben P.</au><au>Grudniewska-Lawton, Magda</au><au>Havenga, Menzo</au><au>Yallop, Christopher</au><au>Hamidi, Ahd</au><au>Gillissen, Gert</au><au>Bakker, Wilfried A.M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2024-04-02</date><risdate>2024</risdate><volume>42</volume><issue>9</issue><spage>2475</spage><epage>2484</epage><pages>2475-2484</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>•AS LNA qPCR can accurately identify VP1-E295K containing samples in sPV2 batches.•The developed AS LNA qPCR for E295K mutation is highly sensitive.•LNA probes used are highly specific in targeting known mutations.•AS LNA qPCR is likely applicable to other vaccine strains, serotypes, and mutations. Sabin Inactivated Poliovirus Vaccine (sIPV) has become one of the preferred vaccination options for the last step in the Poliovirus eradication program. Sequencing of poliovirus samples is needed during the manufacturing of poliovirus vaccines to assure the safety and immunogenicity of these vaccines. Next-generation sequencing analysis is the current costly and time-consuming gold standard for monitoring the manufacturing processes. We developed a low-cost and quick, highly sensitive, and allele-specific locked nucleic acid-probe-based reverse transcription quantitative PCR alternative that can accurately detect mutations in poliovirus vaccine samples during process development, scaling up, and release. Using the frequently in vitro occurring and viral replication-impacting VP1-E295K mutation as a showcase, we show that this technology can accurately detect E295K mutations in poliovirus 2 samples to similar levels as NGS. The qPCR technology was developed employing a synthetic dsDNA fragment-based standard curve containing mixes of E295K-WT (wildtype) and Mut (mutant) synthetic dsDNA fragments ranging from 1 × 107 copies/µL to 1 × 102 copies/µL to achieve a linear correlation with R2 &gt; 0.999, and PCR efficiencies of 95–105 %. Individual standard concentration levels achieved accuracies of ≥92 % (average 96 %) and precisions of ≤17 % (average 3.3 %) RSD. Specificity of locked nucleic acid (LNA)-probes was confirmed in the presence and absence of co-mutations in the probe-binding region. Application of the developed assay to Sabin Poliovirus type 2 production run samples, illustrated a linear relationship with an R2 of 0.994, and an average accuracy of 97.2 % of the variant (allele)-specific AS LNA qPCR result, compared to NGS. The assay showed good sensitivity for poliovirus samples, containing E295K mutation levels between 0 % and 95 % (quantification range). In conclusion, the developed AS LNA qPCR presents a valuable low-cost, and fast tool, suitable for the process development and quality control of polio vaccines.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>38503660</pmid><doi>10.1016/j.vaccine.2024.01.103</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2024-04, Vol.42 (9), p.2475-2484
issn 0264-410X
1873-2518
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11007389
source ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland
subjects Acids
Alleles
AS LNA qPCR
Cost analysis
DNA
Enterovirus C
Immunogenicity
Invoices
Low cost
Manufacturing
Manufacturing industry
mutants
Mutation
Mutations
Next-generation sequencing
NGS
Nucleic acids
Poliomyelitis
Poliovirus
Polymerase chain reaction
qPCR
Quality control
reverse transcriptase polymerase chain reaction
Reverse transcription
Sabin Poliovirus 2
Sarcoma
Sequence analysis
sIPV
vaccination
Vaccine
Vaccines
VP1 protein
VP1-E295K
title High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T17%3A05%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20throughput%20AS%20LNA%20qPCR%20method%20for%20the%20detection%20of%20a%20specific%20mutation%20in%20poliovirus%20vaccine%20strains&rft.jtitle=Vaccine&rft.au=Opmeer,%20Lizet&rft.date=2024-04-02&rft.volume=42&rft.issue=9&rft.spage=2475&rft.epage=2484&rft.pages=2475-2484&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2024.01.103&rft_dat=%3Cproquest_pubme%3E3153183633%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3031680032&rft_id=info:pmid/38503660&rft_els_id=S0264410X24001300&rfr_iscdi=true